25,729 articles
Mixed germ cell tumor
Mixed germ cell tumor (MGCT, ICD-O-3 9085/3) is a rare cancer containing at least two germ cell tumor types, such as embryonal carcinoma, teratoma, yolk sac tumor, choriocarcinoma, or seminoma; it arises most often in the ovary or testicle and is managed as a nonseminoma.
Mixed incontinence
Mixed urinary incontinence (MUI): coexisting stress and urge urinary incontinence per ICS/IUGA definition. Second-most-common UI subtype in women after stress UI; treated by predominant symptom, conservatively first.
Mixed lesions of pinta
Mixed lesions of pinta (ICD-11 1C1E.3; ICD-10-CM A67.3), also called achromic and hyperchromic skin lesions of pinta, is a coding category for pinta, the Treponema carateum skin disease, when depigmented and hyperpigmented lesions coexist.
Mixed lymphocyte culture test
The mixed lymphocyte culture test, also called the mixed lymphocyte reaction, mixes lymphocytes from two people in culture to measure HLA class II mismatch, once used to select transplant donors.
Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas
Pancreatic MiNEN (mixed neuroendocrine-non-neuroendocrine neoplasm), formerly MANEC or mixed exocrine-endocrine carcinoma, is a rare (0.2% of pancreatic tumors) biphasic malignancy with neuroendocrine and ductal or acinar components each ≥30%, five-year survival about 40%.
Mixed rhinitis
Mixed rhinitis (ICD-11 CA08.2), also called mixed allergic and non-allergic rhinitis, is a chronic rhinitis subtype where allergic and non-allergic mechanisms coexist, affecting an estimated 30–50% of chronic rhinitis patients.
Mixed-phenotype acute leukemia
Mixed-phenotype acute leukemia (MPAL), also called biphenotypic or ambiguous-lineage leukemia, is a rare acute leukemia (2-5% of cases) with both ALL and AML features, treated mainly with ALL-like induction plus transplant.
Mixed-type autoimmune hemolytic anemia
Mixed-type autoimmune hemolytic anemia, or mixed AIHA, is a rare form of autoimmune hemolytic anemia where warm IgG and cold IgM autoantibodies together destroy red blood cells.
Miyoshi myopathy
Miyoshi myopathy (MMD1, Miyoshi distal myopathy) is an autosomal recessive distal muscular dystrophy from DYSF mutations, causing calf weakness beginning at 15-30 years; it is the same disease as LGMDR2 (dysferlinopathy).
Mizan al-Tibb
米扎尼·提比 (Mīzān al-ṭibb, ميزان الطب), "The Measure of Medicine," is a Persian Unani medical handbook by Mughal physician Muhammad Akbar Arzani, a foundational 18th-century student textbook now cited in China's Uyghur classic formula directory.
Mizolastine
Mizolastine (Mizollen, Mizolastin) is a second-generation benzimidazole H1 antihistamine, 10 mg once daily for allergic rhinitis and chronic idiopathic urticaria, approved in Europe in 1998, with no demonstrated QTc prolongation but updosing not recommended.
Mk-3415
Mk-3415 (actoxumab, CDA1/GS-CDA1) is Merck's fully human monoclonal antibody against C. difficile toxin A; it failed phase 3 MODIFY trials, its arm stopped for safety, and only bezlotoxumab (MK-6072) was approved.
ML-2
ML-2 (ML2, CVCL_1418, DSMZ ACC-15) is a human acute myelomonocytic leukemia (AML M4) cell line established in 1978 from a 26-year-old man, carrying t(6;11) KMT2A-AFDN fusion and heterozygous KRAS Ala146Thr; sister lines ML-1 and ML-3.
MLS study
MLS study, the Maternal Lifestyle Study (NCT00059540), a 1993-2011 US NICHD Neonatal Research Network observational cohort following 1,388 children prenatally exposed to cocaine or opiates to age 16.
MM1.S
MM1.S, also written MM.1S, is a human multiple myeloma cell line, derived from plasma cells, used widely in myeloma research and known for dexamethasone sensitivity.
MM96
MM96 (CVCL_D848, RRID:CVCL_D848) is a human melanoma cancer cell line from a metastatic lymph node of a 66-year-old female, BRAF V600E positive, parent of the amelanotic subline MM96L.
MMCS trial
MMCS trial (NCT04442672), a completed 2019 interventional study by Zhejiang University's Second Affiliated Hospital, tested tissue oxygen, ultrasound Doppler, thermography, and pulse oximetry against cuff-induced calf pressure in healthy volunteers.
MMR vaccine
MMR vaccine: live attenuated combination vaccine against measles, mumps, rubella; two doses at 12–15 months and 4–6 years; 93–97% effective; contraindicated in pregnancy; no autism link.
MMW Fortschritte der Medizin
MMW Fortschritte der Medizin is a German-language medical journal published by Springer Medizin, formed in 1999 from the merger of the Münchener Medizinische Wochenschrift and Fortschritte der Medizin.
MNH study
MNH study (Maternal Newborn Health Registry, MNHR, NCT01073475): NICHD Global Network prospective population-based pregnancy registry since 2008, enrolling about 60,000 women yearly across seven LMIC sites, tracking stillbirth, neonatal, and maternal mortality to 42 days postpartum.
MOBIL trial
MOBIL trial (NCT01679977, Mobilität im Alter): completed randomized, open-label, factorial-assignment efficacy trial comparing vibrational-proprioceptive resistance exercise training versus neuromuscular electrical stimulation training in 150 adults aged 65-85 with age-related muscle weakness, run 2008-2015 in Austria and Slovakia by the Ludwig Boltzmann Institute.
Mobile Health Units
Mobile Health Units (MHUs, mobile clinics, mobile medical units) are portable facilities delivering diagnostic and therapeutic care to underserved, rural, and conflict-affected communities, defined in MeSH since 1970 and deployed at national scale in the US and India.
MoCA-B Turkish study
MoCA-B Turkish study (NCT07630688): a completed cross-sectional validation of the Turkish Montreal Cognitive Assessment-Basic in 166 low-education adults at Antalya Training and Research Hospital, finding AUC 0.891 for MCI (cut-off 21) and 0.992 for dementia (cut-off 18).
Mocertatug rezetecan
HS-20089 (GSK5733584, mocertatug rezetecan) is a Hansoh-discovered, GSK-licensed B7-H4-targeted antibody-drug conjugate with a topoisomerase I inhibitor payload (DAR 6) in phase 3 trials for platinum-resistant ovarian cancer.
Moclobemide
Moclobemide (Ro 11-1163, Aurorix) is a reversible, selective MAO-A inhibitor (RIMA) antidepressant synthesized in 1972, launched in Europe in 1992, never US-approved, dosed 300-600 mg/day.
Modafinil
Modafinil (Provigil) is a Schedule IV wakefulness-promoting drug approved in 1998 for narcolepsy sleepiness, also used for OSA and shift work disorder in the US but restricted to narcolepsy in the EU.
Model for End-stage Liver Disease score
The Model for End-stage Liver Disease (MELD) score predicts three-month mortality in chronic liver disease from three blood tests, and has prioritized US liver transplant candidates since 2002.
Moderate and severe traumatic brain injury
Moderate and severe traumatic brain injury (moderate-severe TBI) is head trauma more severe than mild TBI, defined by GCS below 13 or prolonged loss of consciousness or amnesia.
Moderate personality disorder
Moderate personality disorder (ICD-11 6D10.1) is the middle severity level of the single ICD-11 personality disorder diagnosis, marked by disturbances in multiple areas of self and interpersonal functioning, specified by five trait domains and a borderline pattern qualifier.
Moderate vision impairment
Moderate vision impairment: ICD-11 distance vision category with presenting acuity worse than 6/18 (20/70) but 6/60 (20/200) or better; also called part of MSVI; mainly caused by uncorrected refractive error and cataract.